News | March 09, 2021
Vivimed Labs receives products approvals from Uzbekistan
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
The price increases are due to the rising costs of raw materials.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
PEL will explore the PLI scheme and apply if its beneficial.
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Subscribe To Our Newsletter & Stay Updated
